



FOR IMMEDIATE RELEASE

Axxam SpA expands to U.S., opens office in Cambridge, Mass.

May 19th, 2016 - Axxam SpA (Milan/Italy), a privately owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive compounds, announced today the opening of its first U.S. office, located in the Cambridge Innovation Center (CIC) in Cambridge, Mass.

“The CIC was the right choice for our first office in the USA,” said Dr. Stefan Lohmer, co-founder and CEO of Axxam. “We consider the Boston area as a unique ecosystem, a kind of gravitation center for biosciences in which talent, business and investment are present and that would allow us to boost our company growth in the perfect environment. Many early stage companies would benefit from our expertise to identify bioactive compounds for their targets using our HTS/HCS platforms and compound collections. We already have a number of strong clients and partners in the area and through our local presence we want to increase the important direct interaction with start-up companies, VCs and pharma/biotech companies.”

Dr. Sarah Murnaghan, Director of Business Development North America, will be managing the U.S. office which is based at the Cambridge Innovation Center 1 Broadway, 14th floor, Cambridge, MA 02142 USA and can be contacted by email: sarah.murnaghan.sm@axxam.com or phone: (857) 320-1018.

More information is available at www.axxam.com.

Axxam SpA is a privately owned innovative Partner Research Organization located at the Science Park Openzone in Bresso (Milan, Italy). The Company is a leading provider of integrated discovery services for the entire Life Sciences industries as: Pharmaceutical, Crop protection, Animal health, Cosmetics and Nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies, including: assay development, compound management, compound collections, HTS, HCS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need.